ProfileGDS5678 / 1451343_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 81% 81% 82% 80% 80% 78% 81% 81% 82% 81% 81% 81% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7565681
GSM967853U87-EV human glioblastoma xenograft - Control 25.803181
GSM967854U87-EV human glioblastoma xenograft - Control 35.8054281
GSM967855U87-EV human glioblastoma xenograft - Control 46.1351482
GSM967856U87-EV human glioblastoma xenograft - Control 55.7641580
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4276980
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2236378
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7178681
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7813581
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.023482
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7841381
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7841781
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8273681
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0622183